Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MICARDIS vs AZILSARTAN MEDOXOMIL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Telmisartan is an angiotensin II receptor antagonist (ARB) that selectively and competitively blocks the binding of angiotensin II to the AT1 receptor, resulting in vasodilation, reduced aldosterone secretion, and decreased blood pressure.
Angiotensin II receptor blocker (ARB) that selectively inhibits angiotensin II binding to AT1 receptors, reducing vasoconstriction, aldosterone secretion, and sympathetic activity.
Treatment of hypertension (FDA-approved),Cardiovascular risk reduction in patients unable to take ACE inhibitors (off-label)
Treatment of hypertension (FDA-approved),Off-label: heart failure, diabetic nephropathy
40-80 mg orally once daily.
40 mg orally once daily. May increase to 80 mg once daily if needed.
Terminal elimination half-life is approximately 24 hours (range 20-30 hours), supporting once-daily dosing. Steady-state achieved in 5-7 days.
Terminal half-life approximately 11 hours; supports once-daily dosing with sustained antihypertensive effect over 24 hours.
Telmisartan is metabolized by glucuronidation via UGT1A3 and UGT2B7; minimal CYP450 metabolism.
Primarily metabolized by CYP2C9 to inactive metabolites; also undergoes esterase-mediated hydrolysis to azilsartan.
Primarily biliary/fecal (approximately 60% as unchanged drug); renal elimination accounts for about 40% (mostly unchanged drug and inactive metabolites). Total recovery in feces: 60-70%; urine: 30-40%.
Biliary/fecal (55% unchanged), renal (42% as inactive metabolites, <1% unchanged)
Highly bound (>99.5%), primarily to albumin and α1-acid glycoprotein. Binding is saturable at high concentrations but clinically not significant at therapeutic doses.
High (>99%) to serum albumin.
Apparent volume of distribution: approximately 500 L (about 7 L/kg), indicating extensive extravascular distribution.
Vd of about 16 L (0.23 L/kg for a 70 kg individual); indicates limited extravascular distribution.
Oral bioavailability is variable, approximately 40-60% (mean 50%) due to first-pass metabolism. Food reduces bioavailability by about 20%, but clinical effect is not significantly altered.
Oral bioavailability approximately 60% under fed conditions (food reduces absorption); absolute bioavailability not determined in humans.
No dose adjustment required for GFR ≥30 m L/min. Not studied in GFR <30 m L/min or dialysis; use caution.
No dose adjustment required for GFR ≥15 m L/min/1.73 m². Not recommended for GFR <15 m L/min/1.73 m² due to lack of data.
Contraindicated in severe hepatic impairment (Child-Pugh class C). For mild to moderate impairment (Child-Pugh A or B), maximum dose is 40 mg once daily.
No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A and B). Not recommended for severe hepatic impairment (Child-Pugh C) due to lack of data.
Safety and efficacy not established in pediatric patients (<18 years).
Not approved for use in pediatric patients (safety and efficacy not established).
No specific dose adjustment needed; start at lower end of dosing range (40 mg) due to possible increased sensitivity.
No specific dose adjustment recommended; initiate at 40 mg once daily. Monitor renal function and blood pressure carefully due to increased sensitivity.
No FDA boxed warning.
none
Fetal toxicity: Use in pregnancy can cause injury and death to the fetus; discontinue when pregnancy is detected.,Hypotension in volume- or salt-depleted patients,Renal function impairment: Monitor serum creatinine and potassium,Hyperkalemia: Risk increased with renal impairment, diabetes, or concomitant K+ supplements/sparing diuretics,Avoid coadministration with aliskiren in patients with diabetes
Fetal toxicity: avoid use in pregnancy,Hypotension in volume-depleted patients,Renal impairment: monitor renal function,Hyperkalemia: monitor potassium levels
Concomitant use with aliskiren in patients with diabetes mellitus,Known hypersensitivity to telmisartan or any component,Pregnancy (second and third trimesters)
Pregnancy (second and third trimesters),Concomitant use with aliskiren in patients with diabetes or renal impairment (e GFR <60 m L/min)
No specific food restrictions. Avoid salt substitutes containing potassium chloride. Maintain consistent dietary habits to avoid fluctuations in blood pressure. Grapefruit juice has no known interaction but other drugs may be affected; consult pharmacist for all medications.
No significant food interactions; can be taken with or without food. Avoid excessive potassium intake from high-potassium foods (e.g., bananas, oranges, spinach, potatoes) or potassium-containing salt substitutes. Limit alcohol intake as it may increase blood pressure or cause dizziness.
Drugs acting directly on the renin-angiotensin system (RAS) can cause fetal and neonatal morbidity and death when used during the second and third trimesters. First trimester exposure does not appear to increase the risk of congenital anomalies, but should be avoided due to potential unknown risks. Oligohydramnios, fetal renal dysfunction, skull hypoplasia, hypotension, and hyperkalemia are risks associated with second and third trimester exposure.
First trimester: Limited human data; animal studies show no teratogenicity. Second and third trimesters: Drugs acting directly on the renin-angiotensin system can cause fetal oligohydramnios, fetal renal dysfunction, skull ossification defects, and neonatal anuria, hypotension, and death.
No data on the excretion of telmisartan into human milk are available. Telmisartan is excreted in the milk of lactating rats. Because of the potential for adverse effects in the nursing infant, a decision should be made to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother. M/P ratio is unknown.
No data on presence in human milk. Manufacturer recommends discontinuing breastfeeding or drug due to potential risk. M/P ratio unknown.
No dose adjustment guidelines are available due to lack of pharmacokinetic studies in pregnancy. However, due to the risks associated with RAS inhibition, telmisartan should be discontinued as soon as pregnancy is detected, and alternative antihypertensive therapy should be initiated if needed.
No dose adjustments during pregnancy; however, use is contraindicated in second and third trimesters due to fetal toxicity. If exposure occurs, discontinue as soon as possible.
Monitor renal function and serum potassium before and during therapy, especially in patients with renal impairment or on potassium-sparing diuretics. May cause a rise in serum creatinine; usually minor and reversible. Avoid use in patients with biliary obstructive disorders or severe hepatic impairment due to primarily biliary excretion. Can be used with or without food; consistency recommended to avoid variability in absorption. Combination with aliskiren is contraindicated in diabetes. Adjust dose in patients with hepatic impairment; initial dose 40 mg once daily.
Azilsartan medoxomil has the highest affinity for AT1 receptors among ARBs; may cause a rapid decrease in blood pressure in volume-depleted patients; avoid use in pregnancy (Category D); monitor renal function and serum potassium; less CYP450 interaction potential than losartan or irbesartan; can be taken without regard to meals; dose adjustment not required in mild-to-moderate hepatic impairment.
Take this medication exactly as prescribed, usually once daily, with or without food. Try to take it at the same time each day.,Do not stop taking this medicine without consulting your doctor, even if you feel well. High blood pressure often has no symptoms.,If you have a pregnancy potential, use effective contraception and notify your doctor immediately if you become pregnant. This drug can harm an unborn baby.,Avoid alcohol and use caution when driving or operating machinery until you know how this medicine affects you, as dizziness may occur.,Do not use salt substitutes containing potassium without your doctor's approval. This medication may increase your potassium levels.,Stay adequately hydrated, especially during exercise or in hot weather, to prevent low blood pressure. Dehydration may increase the risk of low blood pressure.,Report any signs of infection (fever, sore throat) or swelling of the face, lips, or tongue, which may indicate a serious allergic reaction.,Keep all appointments for blood pressure checks and lab work (kidney function and potassium levels).
Take once daily at the same time each day with or without food.,Avoid becoming dehydrated; drink adequate fluids unless directed otherwise.,Do not use if pregnant or planning to become pregnant; notify your doctor immediately if pregnancy occurs.,Do not take with aliskiren if you have diabetes or renal impairment.,Report any signs of angioedema (swelling of face, lips, tongue, difficulty breathing) or severe dizziness.,May cause dizziness, especially during first few days; avoid driving until you know how the medication affects you.,Avoid potassium supplements and salt substitutes containing potassium unless approved by your doctor.,Do not stop taking the medication without talking to your doctor.
No interactions on record
"The combination of azilsartan medoxomil, an angiotensin II receptor blocker (ARB), and fenbufen, a nonsteroidal anti-inflammatory drug (NSAID), can lead to a significant reduction in the antihypertensive and cardioprotective effects of azilsartan. NSAIDs inhibit cyclooxygenase enzymes, reducing prostaglandin synthesis, which diminishes the vasodilatory and natriuretic actions that support blood pressure control mediated by ARBs. This interaction may result in loss of blood pressure control, increased risk of renal impairment (especially in volume-depleted or elderly patients), and potential antagonism of the renal protective effects of ARBs in conditions like heart failure or chronic kidney disease."
"Oxprenolol, a non-selective beta-blocker, may attenuate the compensatory sympathetic response to Azilsartan medoxomil-induced hypotension, potentially leading to an excessive drop in blood pressure. This combination can also result in reduced cardiac output due to additive negative chronotropic effects, increasing the risk of bradycardia and heart block. Clinically, patients may experience severe hypotension, dizziness, syncope, or exacerbated heart failure symptoms."
"The combination of timolol, a non-selective beta-blocker, with azilsartan medoxomil, an angiotensin II receptor blocker (ARB), may lead to an increased risk of hypotension, bradycardia, and additive antihypertensive effects. Timolol can antagonize the compensatory sympathetic response to azilsartan-induced vasodilation, potentially resulting in excessive blood pressure reduction. Additionally, both drugs can affect renal perfusion, raising the risk of renal impairment in susceptible patients."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MICARDIS vs AZILSARTAN MEDOXOMIL, answered by our medical review team.
MICARDIS is a Angiotensin II Receptor Blocker that works by Telmisartan is an angiotensin II receptor antagonist (ARB) that selectively and competitively blocks the binding of angiotensin II to the AT1 receptor, resulting in vasodilation, reduced aldosterone secretion, and decreased blood pressure.. AZILSARTAN MEDOXOMIL is a Angiotensin II Receptor Blocker that works by Angiotensin II receptor blocker (ARB) that selectively inhibits angiotensin II binding to AT1 receptors, reducing vasoconstriction, aldosterone secretion, and sympathetic activity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MICARDIS and AZILSARTAN MEDOXOMIL depend on the specific clinical indication. These are both Angiotensin II Receptor Blocker agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MICARDIS is: 40-80 mg orally once daily.. The standard adult dose of AZILSARTAN MEDOXOMIL is: 40 mg orally once daily. May increase to 80 mg once daily if needed.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MICARDIS and AZILSARTAN MEDOXOMIL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MICARDIS is classified as Category C. Drugs acting directly on the renin-angiotensin system (RAS) can cause fetal and neonatal morbidity and death when used during the second and third trimesters. First trimester expos. AZILSARTAN MEDOXOMIL is classified as Category C. First trimester: Limited human data; animal studies show no teratogenicity. Second and third trimesters: Drugs acting directly on the renin-angiotensin system can cause fetal oligo. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.